BPC-157
Research OnlyAlso known as: Body Protection Compound-157, Bepecin, PL 14736, PL-10
A synthetic peptide derived from human gastric juice protein. Preclinical studies suggest tissue repair properties, but human clinical trial data is extremely limited. A 2025 systematic review of 36 studies found only 1 clinical study.
Research Statistics
Predominantly preclinical; mechanism proposed but unconfirmed in humans; sparse clinical data.
Research Dossier
Overview
What is BPC-157 and what does the research say?
Mechanism of Action
The proposed mechanisms of BPC-157 are based primarily on animal and in vitro studies. Human mechanistic data is lacking.
How It Works (Simplified)
BPC-157 appears to act as a “repair signal” through several pathways:
Promotes new blood vessel formation via VEGF/VEGFR2 pathway activation, improving nutrient delivery to healing tissues.
Activates FAK-paxillin pathway, helping repair cells move to injury sites and attach to healing tissue.
Modulates nitric oxide system - upregulating beneficial vasodilation while reducing inflammatory damage.
Protects gut lining and other tissues from damage, particularly from NSAIDs and other stressors.
Scientific Pathways
VEGF/VEGFR2 Pathway (Angiogenesis)
BPC-157 → VEGFR2 upregulation → PI3K → AKT → eNOS → Nitric Oxide
↓
New blood vessel formationFAK-Paxillin Pathway (Cell Migration)
BPC-157 → FAK/Paxillin phosphorylation → Cell attachment → Migration to injuryKey Research: Hsieh MJ et al. (Taiwan, 2017) demonstrated VEGFR2 activation in wound models. PMID:28013436
Important Limitations
- Nearly all mechanistic studies from single research group (Croatian)
- Translation to human physiology is unconfirmed
- Optimal administration route for systemic effects unknown
- Bioavailability and pharmacokinetics in humans not characterized
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical observations: Initial angiogenic signaling may begin. Animal studies show early VEGF/VEGFR2 pathway activation within days of administration. No human timeline data available.
Animal studies suggest ongoing tissue repair processes. In rat tendon models, improved collagen organization observed by 2-4 weeks. Gastric healing acceleration noted in ulcer models within this timeframe.
Preclinical models show continued tissue remodeling. Rat studies demonstrated improved biomechanical properties of healing tendons. Muscle injury models showed functional recovery improvements.
Long-term animal studies suggest sustained effects on tissue repair pathways. However, human pharmacokinetics, duration of effect, and optimal treatment length are completely unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate BPC-157 product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining BPC-157 with other peptides. Based on published research and mechanistic considerations.
TB-500
SynergisticCommonly combined in research for tissue repair. BPC-157's angiogenic and cytoprotective mechanisms may complement TB-500's actin-regulating and cell migration effects. No direct clinical studies on combination.
GHK-Cu
CompatibleDifferent mechanisms of action (BPC-157 systemic cytoprotection vs GHK-Cu copper-mediated signaling). No known contraindications; both target wound healing pathways through distinct routes.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while Thymosin Alpha-1 modulates immune function. Theoretical complementary benefits for recovery.
LL-37
CompatibleLL-37's antimicrobial properties may complement BPC-157's tissue repair effects in wound healing contexts. No interaction studies available.
Semaglutide
CautionBoth affect GI function. BPC-157 is gastroprotective while semaglutide slows gastric emptying. Unclear if effects interact; monitor GI symptoms if combined.
Melanotan-II
CautionBoth act on various receptor systems. Limited data on interactions. Exercise caution due to lack of combined safety data.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare BPC-157
BPC-157 Calculators
Related Peptides
Cartalax
AED peptide, Ala-Glu-Asp, cartilage bioregulator
A synthetic tripeptide (Ala-Glu-Asp) from Vladimir Khavinson's bioregulator framework, proposed to support cartilage tissue repair and chondrocyte function. All research originates from Russian institutes with no independent Western validation or controlled human clinical trials.
GHK
Glycyl-Histidyl-Lysine, GHK tripeptide, Liver cell growth factor
A naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
Sigumir
Cartilage cytamin, Joint peptides, A-6 cartilage peptides
A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for joint and cartilage support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Related Content
TB-500
Repair & Recovery · moderate evidence
GHK-Cu
Repair & Recovery · moderate evidence
What is BPC-157?
An introduction to BPC-157, its origins, claims, and importa...
BPC-157 vs Chonluten
View side-by-side analysis
BPC-157 vs GHK-Cu vs TB-500
View side-by-side analysis